Dementia and Alzheimer's Disease is on Nov 23 2023 at Paris

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme

Discovering the Emerging Challenges in the Era of Dementia and Alzheimer's Disease

- Dementia 2023

Welcome Message

On behalf of the Organizing panel, we are delighted to welcome enthusiastic investigators from all over the world to join us at the 16^thInternational Conference on Dementia and Alzheimer's Disease, slated for the 23-25 of November, 2023 in London, United Kingdom.

Dementia 2023 revolves around the theme of "Discovering the Emerging Challenges in the Era of Dementia and Alzheimer's Disease," and the conference includes keynote bestowals, poster presentations, E-poster exhibits, oral addresses, and exhibitions.

The Dementia 2023 is a fantastic platform for great scientists, youthful researchers, croakers, nursing staff, academics, neurosurgeons, neurologists, and other health professionals to share in international plants, present their exploration, and partake their gests on all aspects of this fleetly growing field, allowing them to showcase their rearmost ways and enhance their skills.

We hope the Conference will invigorate you and inspire you to generate new ideas.

Regards,

Organizing committee

Dementia 2023

Market Analysis

Dementia is a broad spectrum of mental diseasesthat, over time, weaken a person's capacity for thought and memory. The causesof Dementia are still unknown, despiteimprovements in science and medicine. The condition is therefore solely managedsymptomatically.

The Dementia treatment is supportive and seeks tolessen the severity of the symptoms, however movement problems like Parkinson's are recognisedto be a trigger for Dementia in many cases. According to Data Bridge Market Research'sanalysis, the market for Dementia treatments would expand from 2022 to 2029 ata CAGR of 8.50%.

Dementia is a word used todescribe a loss of memory, language, problem-solving, and other thinkingabilities that is severe enough to affect daily life. The most common cause of Dementiais Alzheimer’s disease. Dementia is not a singledisease; it’s an umbrella term that encompasses a wide range of medicalproblems, including Alzheimer’s disease, similar to heart disease. Abnormalbrain alterations create the disorders included under the umbrella term “Dementia.”These alterations cause a deterioration in thinking abilities, also known ascognitive capacities, that is severe enough to interfere with daily life andindependence.

The treatment of diversemental problems across the world's population is profiting from thefast-accelerating technical innovations and treatment methods in mental healthcare. The result of these achievements is the treatment of Dementia syndromes and behavioralimpairments. Through the projected period, the therapy for syndromes of Dementiacare market may experience marked increase due to the rising awareness ofmental health.

Regionals Insights

Dementia affects around 944,000 people across theUK with some areas having a greater number of people living with Dementia thanothers.

To help show this distribution, the maps linkedbelow provide a visual and interactive representation of Dementia prevalence by four different geographic entities; Westminsterconstituencies for the UK, Integrated Health Boards for England (replacingClinical Commissioning Groups as of July 2022), and Local Health Boards forScotland and Wales.

These tools are developed by using publishedpopulation data and prevalence rates of the condition to estimate the totalnumbers of people in each area with Dementia, for 2015. Eachfive-year age band from 30-34 up until 95+ has an associated Dementiaprevalence rate (an estimated percentage of that age group with Dementia) fromthe Dementia UK: Update 2014 report and these rates are then multiplied by thepopulation data.

In areas with larger populations and olderpopulations, there will be a higher number of people living with Dementia, asage is the greatest risk factor.

Dementia is one of society’s greatest healthchallenges and one of the most important issues the country faces as itspopulation ages. In London alone, there are currently more than 72,000 peopleliving with the illness. By 2015, 850,000 older people will be diagnosed withthe disease in the UK and if current trends stay the same this number isexpected to pass two million by 2051. Latest research estimates that the costof Dementia to the UK has hit£26 billion a year and £604billion worldwide - far exceeding the cost to theeconomy of cancer and heart disease. Despite the scale of the problem, in thelast 15 years only three new drugs have come to market.

Dynamics of the Dementia Treatment Market

Opportunities

Public and private organisations areinvesting more in R&D. The Dementia associated with Alzheimer's disease marketis anticipated to grow over the course of the forecasting period as a result ofexpanding R&D efforts in disease-modifying medications as well as increasedinvestments by major players in clinical studies of cutting-edge treatmentalternatives.

Restraints/Challenges

However, it is anticipated that stringentgovernment rules controlling product approval and the high expenses connected withR&D operations will hamper market expansion.

This Dementia treatment marketresearch contains latest advancements, trade regulations, import-exportanalysis, production analysis, value chain optimization, market share, effectof domestic and localised market players, assesses opportunities in terms ofdeveloping revenue pockets, changes in market regulations, strategic marketgrowth analysis, market size, category market growths, application niches anddominance, product approvals, product launches, and geographic informationsystems. Contact Data Bridge Market Research for an Analyst Brief to learn moreabout the market for Dementia treatments. Our staff will assist you in makingan informed choice to develop your market.

Patient Epidemiology - Analysis

By 2022, there will be more than 50 million peopleliving with Dementia worldwide, predicts Alzheimer's DiseaseInternational. Every 20 years, this number is anticipated to more than double,rising to 82 million in 2030 and 152 million in 2050.The study is expected toconclude in December 2023 and started in June 2020.

The market for Dementia treatments also offers youa thorough market study of patient analysis, prognosis, and treatments. Datavariables included in the report include prevalence, incidence, mortality, andadherence rates. To develop a more reliable and cohort multivariate statisticalmodel for projecting the market during the growth period, direct or indirectimpact analyses of epidemiology on market growth are examined.

The Impact of Covid-19 on the Dementia TreatmentMarket

The market for Dementia medications isanticipated to be significantly impacted by the COVID-19 pandemic epidemic.Patients with Dementia are more likely to become infected with COVID-19 becauseit is more challenging for them to adhere to the safety recommendations made toprevent viral spread due to their cognitive impairments. Furthermore, comparedto younger people without Dementia, older populations with Dementia are morelikely to experience more serious health effects. The COVID-19 pandemic isanticipated to negatively impact new product launches, which are anticipated tobe the primary driver of market expansion.

KeyMarket Trends

The Alzheimer’sDisease Segment Dominates the Market and is Expected to Continue the Same Overthe Forecast Period.

The Alzheimer'sdisease segment is expected to hold a major market share over the forecastperiod owing to factors such as the increasing burden of Alzheimer's disease andongoing research and development of drugs for Alzheimer's.

The increasingcompany focus on research and development activities for developing effectivetreatment drugs for patients with Alzheimer's disease is expected to drive thesegment growth over the forecast period. For instance, as per the Alzheimer’s Association 2022 report, the United States Foodand Drug Administration (FDA) approved five drugs for the treatment ofAlzheimer’s, namely rivastigmine, galantamine, donepezil, memantine, and memantinecombined with donepezil. As per the same source, the vast majority of peoplewho develop Alzheimer’s Dementia are aged 65 years or older. This is calledlate-onset Alzheimer’s. To learn more about the key trends in Dementia andAlzheimer’s disease, join the Dementia 2023 Conferences.

METRICS

Allied academies organize international multidisciplinary conferences on cutting-edge basic and applied research in life sciences, pharmaceuticals, medicine, healthcare, and nursing, which are delivered by the brightest minds in industry and academia and intend to bring together researchers, principle investigators, subject matter experts, business representatives, scientists, and students from all over the world to create a worldwide venue for the transmission of unique research findings, novel ideas,and hands-on development experiences.

Dementia 2023 is specifically premeditated with a unifying axiom to provide a pulpit to widen the imminent scientific creations.It will truly provide an international platform to spread your research work and exchange with your global community and enhance your professional skills.

Allied academies' posting conference details on their official pages will help to reach the intended target audience. Posting the web-page links on social media reaches many people, and it will give a great experience to learn about the conference in detail.

About

Dementia 2023 has been planned into a multitude of tracks of Neuroscience to choose from every segment and provide you with a unique opportunity to meet up with industrialized and academic peers in the Neuroscience field and establish scientific contact between them. We cordially invite all concerned people in Neuroscience, Dementia, and Alzheimer’s research to come and participate with us at our Dementia 2023 and make it successful with your participation. Dementia 2023 has Eminent OCM, Keynote Speakers, Renowned speakers, and Exhibitors from the Neuroscience field as a part of the congress.

This Dementia Event will be organized under the Theme of “Fostering the Latest Challenges in the Era of Dementia and Alzheimer's Disease”.

At Allied academics, it's our ideology to bring maximum exposure to our participants, so we confirm that the event may be a blend that covers professionals like Neurologists, Neurosurgeons, Neuroscientists, Professors of, and Personnel from academia and industry, making the Dementia 2023 Annual Meeting perfect.

We invite you to join us at the, where you'll be certain to possess a meaningful experience with scholars from around the world. All members of the Dementia 2023 organizing committee look forward to meeting you in London, UK.

Past Conference Report

With great support from our Organizing Committee, Allied Conferences successfully completed the"15th World Congress on Dementia and Alzheimer's Disease", which was held in the form of a Virtual Event(Webinar) on November 21, 2022.

First and foremost, we appreciate your faith in us and your participation in Dementia 2022, a worldwide conference focused on many aspects of Dementia, Alzheimer, Parkinson and Neurology. There are several ways to express our gratitude to you for organizing a fantastic virtual gathering for Dementia 2022. The meeting was marked by the participation of young and inventive scientists, industrial participants, and imaginative student groups from more than 20 countries, all of whom contributed to the success of this activity.

The congress proceedings are organized using a variety of scientific and plenary meetings. The meeting began with an opening ceremony, which was followed by a series of talks by both Honourable Guests and respective Keynote Panel members. The experts who brought the subject to life via their amazing presentations and testimonies from keynote speakers and seminars

Donna de Levante Raphael | Alzheimer’s Foundation of America | USA
Soni Shrestha | Oslo Municipality | Norway
Sumanth S Hiremath | Rani Channamma University | India
Laura Ion | Selinus University of Sciences and Literature | Italy

The event brought together diverse fields of Dementia with seminars and plenary talks by the presentative from various universities and organizations

Amanda F. Rose | Cleveland Clinic Akron General | USA
Ojes Xavier | St. Albert’s College| India
Brandon Lucke-Wold | Co-Founder at SwiftScience |USA
Tamas Fulop | University of Sherbrooke | Canada
Nadya Kagansky | Tel-Aviv University affiliated | Israel
Pooja Chandrashekar | All India Institute of Speech and Hearing | India
Rahimi F | Tehran University of Medical Sciences | Iran
Omer Eladil A. Hamid | Faculty of Medicine IUA | Sudan

With the great response and feedback which we received at this event, Allied conferences are proud to announce our upcoming conference entitled "16th International Conference on Dementia and Alzheimer's Disease," scheduled to be held on November 23-25, 2023 in London, UK.

We would like to see your pleasant participation, constructive engagement, and support in order to make this activity a success again.

AWARD’S AND BENEFITS

“Winning isn’t everything in life; it’s the only thing.”

Make memories and share your thoughts on this fantastic platform which is loaded with a bundle of opportunities and moments to capture.

Awards:

Best poster benefits:

A unique opportunity to combine visual and oral explanations of your projects in the form of a poster presentation.
The accepted poster abstracts will be published in renowned and supporting international journals with a unique DOI given by CROSSREF.
The best posters will have the opportunity to publish their entire research paper for a reduced processing fee in supporting international journals.

Young scientist benefits-

Advancing perfection and perceiving remarkable commitments made by the youthful researchers for their work done essentially during the span of study.
Find out about career advancement and the most recent research devices and technologies in your field.
Graduates are motivated by the chance to choose neighbourhood or worldwide subjects of pertinence or enthusiasm to them and build up their own logical examinations and models, drawing in locally or universally.
The Award will be given to two chosen researchers.
Chances to be a student envoy.
Chances to collaborate with partners from all over the world.
Discounts at the Allied conferences, at different worldwide venues in the future.
Chances to publish full-length articles in the conference's reputed supporting global publications of the respective congress.
The Board of Directors nominates the Best Young Scientist Award, and if they wish to publish a full-length paper, they can publish it in the supporting global journals of the respective conference with no preparation fees.

Congress Opportunities

For Researchers and Faculty Members:

Speaker Presentations
Poster Display
Symposium hosting (4-5 member team)
Workshop organizing

For Universities, Associations & Societies:

Association Partnering
Collaboration proposals
Academic Partnering
Group Participation

For Students and Research Scholars:

Poster Competition (Winner will get Best Poster Award)
Young Researcher Forum (YRF Award to the best presenter)
Student Attendee
Group registrations

For Business Delegates:

Speaker Presentations
Symposium hosting
Book Launch event
Networking opportunities
Audience participation

For Product Manufacturers:

Exhibitor and Vendor booths
Sponsorship opportunities
Product launch
Workshop organizing
Scientific Partnering
Marketing and Networking with clients

Sessions/Tracks

The international scientific committee of Dementia 2023 invites participants to submit abstracts on the below-mentioned congress tracks:

Dementia
Alzheimer Disease
Parkinson’s Disease
Neurodegenerative Diseases
Stages of Dementia
Vascular Dementia
Frontotemporal Dementia
Neuropharmacology
Geriatrics Dementia and Cognitive Disorder
Neuroepigenetics
Aging and Dementia
Role of Amyloid Protein in Alzheimer’s and Dementia
Bioinformatics Approach for Dementia
Recent Advancements in the Diagnosis of Dementia
Case Reports in Dementia
Treatment Modalities for Dementia
Causes and Prevention of Dementia
Dementia Care, Practice, and Awareness

Track 1: Dementia

Dementia is a broad category of brain diseases that causes a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning. Alzheimer’s disease is the most common type of disease which covers 50-70% cases. The common symptoms of Dementia include emotional constraints, a problem in finding words, lack of motivation etc. The severity of Dementia increases with a person’s age. The other common types of diseases which include Dementia are Vascular dementia, Lewy body dementia and Frontotemporal dementia. Worldwide, with Dementia or Related disorders nearly 44 million people have suffered in 2015, past results showed 35.66 million population lived with Dementia worldwide in the year 2010, with numbers expected to nearly double every twenty years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, fifty-eight per cent of all population with dementia lived in countries with lower or moderate incomes, with this proportion anticipated to rise to 63% till 2030 and 71% by 2050. This condition is anticipated to double by 2030 and quite triple by 2050 to 115 million.

Related Association and Societies: The World Dementia Council, Association for Frontal Temporal Degeneration, Association for Dementia Care, Grenada Alzheimer’s Association, Society of Dementia Australia, The Alzheimer Society of Ireland, Saudi Alzheimer’s Disease Association, Primary Progressive Aphasia, Alzheimer's Research & Prevention Foundation, Alzheimer’s and Dementia Association of the Cayman Islands (ADACI).

Related Journal: Dementia Journal, European Journal of Preventive Dementia in Oxford Academic, Journal of Neurosurgery, Neurology and Neurosurgery Journals, Journals of associated Neurology, Journal of the Neurological Sciences, Journal of Neuroscience, Brain Disorder Journal, Journal of Neuroscience Research, Asian Journal of Psychiatry.

Track 2: Alzheimer Disease

Alzheimer is the most common category of Dementia. It is a chronic Neurodegenerative Disorder and caused by brain cell death. The symptoms of brain cell death are memory loss, disorientation and cognitive decline. The size of the brain shrinks and the nerve cells and attachments in the tissues progressively reduced, which cannot be diagnosed in the living brain affected by Alzheimer's disease, post- mortem/autopsy will always show tiny inclusions in the nerve tissues, called as plaques and tangles. Plaques are found between the dying cells in the brain - from the build-up of a protein called Beta-amyloid (amyloid plaques). The tangles exist in the brain neurons, from the disintegration of the second protein, called Tau. There are no existing treatments or preventive measures to stop or cure Alzheimer’s. Most of the patients with Alzheimer’s are above 65 years of age but 4-5% cases are of early onset Alzheimer’s Disease.

Related Association and Societies: Society of Dementia and Alzheimer Disease, Alzheimer Society of Canada, United against Dementia age UK, Oman Alzheimer’s Society | Lewy Body Dementia Association, Parkinson’s Disease Foundation, Alzheimer’s & Related Disorders Society of India, Society of Alzheimer New Zealand, Dementia Society of America, National Stroke Association.

Related Journal: Frontiers in Dementia, Journal of Dementia Care, Dementia and Geriatric Cognitive Disorders, The Journal of Neuroscience, Journal of Dementia care (UK), Nature Reviews Neuroscience, Trends in Neuroscience, Annual Review of Neuroscience, Progress in Dementia, European Journal of Neuroscience.

Track 3: Parkinson’s Disease

Parkinson's disease Dementia is a cognitive decline in thinking and reasoning that develops in the person diagnosed with Parkinson's disease at least a year earlier. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms. Hence this conference will provide a platform to discuss the problem.

Related Journal: Dementia Journal, European Journal of Preventive Dementia in Oxford Academic, Journal of Neurosurgery, Neurology and Neurosurgery Journals, Journals of associated Neurology, Journal of the Neurological Sciences, Journal of Neuroscience, Brain Disorder Journal, Journal of Neuroscience Research, Asian Journal of Psychiatry.

Track 4: Neurodegenerative Diseases

Neurodegeneration is the progressive loss of structure or function of neurons, including the death of the nerve cells. It can cause your brain and nerves to deteriorate over time. The neurological conditions in which the Dementia occurs include some disorders like Parkinson's disease, Normal Pressure Hydrocephalus, Huntington's disease, and Creutzfeldt-Jakob disease (CJD). These diseases mimic Dementia or have Dementia as a major sign in the disease. The genetic factors are responsible for the establishment of disorders like Parkinson’s disease, Down Syndrome, Creutzfeldt-Jakob disease, Normal Pressure Hydrocephalus. The other factors for Dementia include physical factors like head injuries and Traumatic brain injuries.

Track 5: Stages of Dementia

Depending on the type of dementia a person has, the disease's signs and symptoms will change over time. Here are some of the dementia types that are most frequently identified: Alzheimer's disease, Parkinson's disease. Some others common types are Dementia with Lewy bodies, Vascular dementia, Frontotemporal dementia, Mixed dementia.

Track 6: Vascular Dementia

Vascular dementia is the second most common type of Dementia after Alzheimer’s Disease. It is also called Multi-Infarct Dementia (MID) and Vascular Intellectual Impedance (VCI), is caused by issues in the supply of blood to the mind, normally a progression of minor strokes. Dementia is a general term describing problems with reasoning, planning, judgment, memory, and other thought processes caused by brain damage from impaired blood flow to your brain. People with dementia give dynamic subjective hindrance, intensely or subacutely as in mellow psychological debilitation, every now and again step-wise, after various cerebrovascular occasions (strokes). A few people may seem to enhance amongst occasions and decrease after more noiseless strokes. A quickly decaying condition may prompt demise from a stroke, coronary illness, or infection. Dementia can be caused by ischemic or haemorrhagic infarcts influencing numerous mind regions, including the foremost cerebral supply route domain, the parietal projections, or the cingulate gyrus.

Track 7: Frontotemporal Dementia

Frontotemporal Dementia is characterised by gradual impairment to either or both of the brain's frontal or temporal lobes. The following things may be impacted: personality, attitude, vocabulary, and motion. Most of the time, especially in the first phases of the illness, memory is unaffected. Diagnoses of frontotemporal dementia are more frequently made in adults under 65. How long a person with FTD will survive is uncertain. Depending on their diagnosis, some people go on to survive for more than ten years while others just make it to two.

Track 8: Neuropharmacology

The action of a drug on the nervous system and the neural mechanisms through which they influence behaviour is studied in neuropharmacology. Studying these interactions will help the researchers in developing drugs to treat neurological disorders, psychological disorders, pain, addiction and other diseases. Drug development in Dementia and Alzheimer’s Disease is based on evolving pathophysiological theory.

Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies. Rigorous clinical trials on Dementia drugs are continuing in the USA and UK under the guidance of Alzheimer's society and it is reported that there is very less participation of people. Most of the drugs are in the second and third phases. New medications for Dementia being developed in 2014/2015, 31% were named symptoms modifying. Such Dementia meetings will help researchers to know target areas for Drug development in Dementia and work towards it and also Dementia conferences exhibit clinical trial medications and offer positivity to discover new approaches in curing Dementia.

Track 9: Geriatrics Dementia and Cognitive Disorder

Geriatrics or geriatric medication may be a speciality that focuses on the health care of older people. It aims to push health by preventing and treating diseases and disabilities in older adults. there's no set age at that patients are also underneath the care of a specialist or geriatric MD; an MD United Nations agency makes a speciality of the care of older people. Rather, this call is set by the individual patient’s needs, and therefore the availableness of a specialist. It’s vital to notice the distinction between gerontology, the care of aged people, and geriatrics, that is that the study of the ageing method itself. Cognitive disorders square measure a class of mental state disorders that primarily influence learning, memory, perception, and drawback determination, and embody blackout, dementia, and delirium. Whereas anxiety disorders, mood disorders, and psychotic disorders can even have an effect on psychological feature and memory functions, the DSM-IV-TR doesn't contemplate these psychological feature disorders, because of the loss of cognitive function is not the primary (causal) symptom. Causes vary between the various sorts of disorders, however, must include damage to the memory parts of the brain. Treatments rely on however the disorder is caused. Medication and therapies square measure the foremost common treatments but, for a few sorts of disorders like amnesia, treatments will suppress the symptoms however there is presently no cure.

Track 10: Neuroepigenetics

Neuroepigenetics is the field in Neurobiology that replaces the conventional thoughts on heritable epigenetic mechanisms, which involves in histone and chromatin modification which results in the variable expression of genes in the CNS and results in the Dementia. The numerous Neuroepigenetic mechanisms have been involved in several neurological and neurodegenerative diseases for the regulation of various epigenetic mechanisms. All the mechanisms in epigenetics will have a biochemical characteristic such that it helps in the regulation process. The basic principle of Neuroepigenetics is that once DNA methylation patterns are established upon the genome in terminally differentiated cells, those modifications are permanent and essentially immutable. Other epigenetic molecular mechanisms are also in play in neurons. Some are ATP-dependent chromatin remodelling, genomic imprinting, SNF2 chromatin remodelling.

Track 11: Aging and Dementia

Human brains change as people age, but Alzheimer's disease and related dementia are not an unavoidable part of the process. In fact, it may be possible to delay or prevent up to 40% of Dementia cases. Understanding what is and is not normal in terms of brain health is helpful. Slow response rates and difficulty multitasking may be signs of normal brain ageing, but daily memory, skills, and knowledge are constant with age and may even get better. It's common to often lose track of recent events, such as where you put your keys or a new acquaintance's name.

Track 12: Role of Amyloid Protein in Alzheimer’s and Dementia

The amyloid plaques and neurofibrillary tangles formation are thought to contribute to the degradation of the neurons (nerve cells) in the brain and the subsequent symptoms of Alzheimer's disease.Amyloid Plaques: One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. Amyloid generally indicates protein fragments that the body produces normally. Beta-amyloid is a protein fragment from an amyloid precursor protein (APP). In a healthy brain, these protein fragments are broken down and get eliminated. In Alzheimer, the fragments get accumulated to form hard & insoluble plaques.

Track 13: Bioinformatics Approach for Dementia

Bioinformatics advent can be used to regulate and evaluate data from the current high-throughput research technologies and render means for novel discoveries in the field of Neurodegenerative Diseases. It is reported that there is very little published data on Epigenomics. It is said that the data are obtained from high throughput technologies in the screening of the human brain. These data intend the upcoming researchers to know and design their experiments. Data Mining plays an important role in the prediction of the disorder, where the actual data is compared with the real data and the results are interpreted. The Transcriptomics and Proteomics studies have also been carried out providing necessary solutions for the problems.

Track 14: Recent Advancements in the Diagnosis of Dementia

The assessment of Dementia in needed to rule out similar symptoms showing to such diseases such as depression, delirium which is curable. It is necessary to provide time to Dementia patients to plan the future and make them literate about the possible effects in the future. There are various tests for diagnosing Dementia such as Mini-Mental State Examination (MMSE), Mental Score Test, Trail Making Test. MMSE test includes a series of exercises in which various problems are checked with memory, speech, ability to respond. A blood test is also done to check levels of vitamin B12 and Thyroid hormones, which may be responsible. Brain scans such as MRI and CT scans used for checking brain tumour and Strokes in Vascular Dementia. Neurology gatherings talked rigorously on Dementia Diagnosis and it is always misleading to different conditions like Parkinson’s' disease. Hence discovery and establishment of new methodologies and techniques for analysis are in the urge for the Dementia society for dependable diagnosis methods.

Track 15: Case Reports in Dementia

The goal of much of the research activity in Dementia is to develop interventions for 'treatment' or even 'cure'. The classical bench to bedside paradigm has been disappointing in dementia. There is a long list of putative dementia treatment compounds with favourable pre-clinical and early phase trial data that have been neutral or even potentially harmful when assessed in phase III studies. Lewy body dementia is a common but frequently underdiagnosed cause of Dementia often mistaken for the more familiar entity of Alzheimer disease. Clinically the distinction is important because it can have profound implications for management. The diagnosis of Lewy body dementia has important implications. It is associated with a high incidence of neuroleptic sensitivity, necessitating great caution in the use of these common antipsychotic agents. Early studies indicate cholinesterase inhibitors can be beneficial for treating the hallucinations and behaviour disturbances that afflict these patients and might also improve cognition.

Track 16: Treatment Modalities for Dementia

Treatment modality is a method that is followed to treat a patient suffering from a disease condition. The treatment modalities have three main approaches, which includes medical, psychological and sociocultural approaches. The most important consideration is that, in practice, no single treatment is considered sufficient for the treatment of Dementia. By now the combination therapy which involves the use of two or more drugs proves to be efficient. The other treatment methods which involve the stem cell therapy and gene therapy has now created the spotlight in the Dementia Treatment. Hence the advanced treatment methods can be discussed in the conference.

Track 17: Causes and Prevention of Dementia

Dementia is challenging to prevent because its causes are frequently unknown. However, individuals with Dementia brought on by a stroke might be able to delay further losses by reducing their risk of heart disease and stroke. These tactics can improve your general health even if you don't have these known risks Reduced blood pressure, talk about diabetes, give up smoking, Reach and keep a healthy weight, Increase your level of exercise.

Track 18: Dementia Care, Practice and Awareness

Dementia is a predominant disorder that affects a greater number of people around the world. Diagnosis of the patient with Dementia frightens the person affected by the syndrome, their family members and caretakers. A better understanding of public awareness of Dementia aids more effective health and social policies. Dementia patients need assistance and full-time care as much as drugs. Some common care practices in Dementia are assistance in food and fluid consumption, pain management, social engagement ensuring safety and security of Dementia patients. The main aim of care practices is to ensure cut in hospitalization and psychotropic drugs. Understanding patient’s mood changes, particular behaviour, speech problems and help in rectifying them. Dementia patients need end of life care, so qualified nursing staff is needed. Few care practices which are used are indoor and outdoor activities, visual and audio stimulation, Art therapy. Care practices in Dementia have been critical to engage in International Dementia meetings. In order to evolve in Dementia care, world gathering and genuine talks on Dementia care are required. The Dementia conference discusses public awareness as well as care practices to achieve a higher rate of early diagnosis and to decrease the distress among the patient, family and caregivers.

Related Journal: Frontiers in Dementia, Journal of Dementia Care, Dementia and Geriatric Cognitive Disorders, The Journal of Neuroscience, Journal of Dementia care (UK), Nature Reviews Neuroscience, Trends in Neuroscience, Annual Review of Neuroscience, Progress in Dementia, European Journal of Neuroscience.